C9orf72 and frontotemporal dementia: Of the papers included, approximately half used C9orf72 mutation-positive subjects (n = 49) whilst the remaining papers attempted to recapitulate C9-ALS/FTD pathology in either in vitro models (n = 28) or in vivo models (n = 30).